Gene · 90
Papers2,859
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,859
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Activin A plays an essential role in migration and proliferation of hepatic stellate cells via Smad3 and calcium signaling. | Sci Rep | 2024 | 39223291 | PubTator, text mining | PubMed |
| Leveraging multiple data types for improved compound-kinase bioactivity prediction. | Nat Commun | 2024 | 39217147 | PubTator, text mining | PubMed |
| Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. | Cancer Res | 2024 | 39207369 | PubTator, text mining | PubMed |
| Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe. | Biomolecules | 2024 | 39199396 | PubTator, text mining | PubMed |
| Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies. | Discov Oncol | 2024 | 39190097 | PubTator, text mining | PubMed |
| Momelotinib: Mechanism of action, clinical, and translational science. | Clin Transl Sci | 2024 | 39189872 | PubTator, text mining | PubMed |
| BMP10 accelerated spinal astrocytic activation in neuropathic pain via ALK2/smad1/5/8 signaling. | Front Pharmacol | 2024 | 39188955 | PubTator, text mining | PubMed |
| Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses. | Sci Rep | 2024 | 39169044 | PubTator, text mining | PubMed |
| Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial. | Int J Hematol | 2024 | 39110143 | PubTator, text mining | PubMed |
| MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. | Ann Hematol | 2024 | 39073589 | PubTator, text mining | PubMed |
| Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification. | Sci Transl Med | 2024 | 39047114 | PubTator, text mining | PubMed |
| Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib. | Clin Lymphoma Myeloma Leuk | 2024 | 39034203 | PubTator, text mining | PubMed |
| Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2. | J Med Chem | 2024 | 39023313 | PubTator, text mining | PubMed |
| TGFβ signaling pathway is altered by HLA-B27 expression, resulting in pathogenic consequences relevant for spondyloarthritis. | Arthritis Res Ther | 2024 | 39010233 | PubTator, text mining | PubMed |
| Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. | Adv Ther | 2024 | 38990433 | PubTator, text mining | PubMed |
| Momelotinib - a promising advancement in the management of myelofibrosis in adults with anemia. | Front Oncol | 2024 | 38983933 | PubTator, text mining | PubMed |
| ACVR1/ALK2-p21 signaling axis modulates proliferation of the venous endothelium in the retinal vasculature. | Angiogenesis | 2024 | 38955953 | PubTator, text mining | PubMed |
| AMPK induces PIAS3 mediated SUMOylation of E3 ubiquitin ligase Smurf1 impairing osteogenic differentiation and traumatic heterotopic ossification. | Biochim Biophys Acta Mol Cell Res | 2024 | 38844181 | PubTator, text mining | PubMed |
| Prediction of the Signaling Pathway in Polycystic Ovary Syndrome Using an Integrated Bioinformatics Approach. | Gynecol Obstet Invest | 2024 | 38810612 | PubTator, text mining | PubMed |
| Gprc5a is a novel parathyroid hormone-inducible gene and negatively regulates osteoblast proliferation and differentiation. | J Cell Physiol | 2024 | 38769895 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/90/papers?page=7